Cited by

• Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.

  Carrieri P, Carrat F, Di Beo V, Bourlière M, Barré T, De Ledinghen V, Pageaux GP, Bureau M, Cagnot C, Dorival C, Delarocque-Astagneau E, Marcellin F, Pol S, Fontaine H, Protopopescu C; ANRS CO22 HEPATHER study group. Carrieri P, et al. JHEP Rep. 2022 Mar 30;4(6):100481. doi: 10.1016/j.jhepr.2022.100481. eCollection 2022 Jun. JHEP Rep. 2022. PMID: 35514789 Free PMC article.
• Natural history of HCV infection.

  Sarin SK, Kumar M. Sarin SK, et al. Hepatol Int. 2012 Oct;6(4):684-95. doi: 10.1007/s12072-012-9355-6. Epub 2012 Mar 9. Hepatol Int. 2012. PMID: 26201520
• Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.

  Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, Taguri M, Koike K. Sato M, et al. PLoS One. 2014 Mar 17;9(3):e91822. doi: 10.1371/journal.pone.0091822. eCollection 2014. PLoS One. 2014. PMID: 24637774 Free PMC article.
• Epidemiology of Hepatitis C Virus in HIV Patients from West Mexico: Implications for Controlling and Preventing Viral Hepatitis.

  Jose-Abrego A, Trujillo-Trujillo ME, Laguna-Meraz S, Roman S, Panduro A. Jose-Abrego A, et al. Pathogens. 2024 Apr 27;13(5):360. doi: 10.3390/pathogens13050360. Pathogens. 2024. PMID: 38787212 Free PMC article.
• Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

  Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Margusino-Framiñán L, et al. Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7. Eur J Hosp Pharm. 2020. PMID: 32296504 Free PMC article.